Diebold Nixdorf, Incorporated
Diebold Nixdorf, Incorporated Fundamental Analysis
Diebold Nixdorf, Incorporated (DBD) shows weak financial fundamentals with a PE ratio of 27.83, profit margin of 2.49%, and ROE of 8.82%. The company generates $3.8B in annual revenue with weak year-over-year growth of -0.25%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 36.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze DBD's fundamental strength across five key dimensions:
Efficiency Score
WeakDBD struggles to generate sufficient returns from assets.
Valuation Score
ModerateDBD shows balanced valuation metrics.
Growth Score
WeakDBD faces weak or negative growth trends.
Financial Health Score
ModerateDBD shows balanced financial health with some risks.
Profitability Score
WeakDBD struggles to sustain strong margins.
Key Financial Metrics
Is DBD Expensive or Cheap?
P/E Ratio
DBD trades at 27.83 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, DBD's PEG of 0.31 indicates potential undervaluation.
Price to Book
The market values Diebold Nixdorf, Incorporated at 2.39 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.76 times EBITDA. This is generally considered low.
How Well Does DBD Make Money?
Net Profit Margin
For every $100 in sales, Diebold Nixdorf, Incorporated keeps $2.49 as profit after all expenses.
Operating Margin
Core operations generate 7.55 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.82 in profit for every $100 of shareholder equity.
ROA
Diebold Nixdorf, Incorporated generates $2.45 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Diebold Nixdorf, Incorporated generates limited operating cash flow of $297.11M, signaling weaker underlying cash strength.
Free Cash Flow
Diebold Nixdorf, Incorporated produces free cash flow of $243.07M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $6.78 in free cash annually.
FCF Yield
DBD converts 9.48% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
27.83
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.31
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.39
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.68
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.07
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.30
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How DBD Stacks Against Its Sector Peers
| Metric | DBD Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 27.83 | 34.43 | Better (Cheaper) |
| ROE | 8.82% | 1135.00% | Weak |
| Net Margin | 2.49% | -134663.00% (disorted) | Weak |
| Debt/Equity | 1.07 | 7.92 | Strong (Low Leverage) |
| Current Ratio | 1.30 | 5.77 | Neutral |
| ROA | 2.45% | -310462.00% (disorted) | Weak |
DBD outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Diebold Nixdorf, Incorporated's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
73.56%
Industry Style: Growth, Innovation, High Beta
High GrowthEPS CAGR
90.26%
Industry Style: Growth, Innovation, High Beta
High GrowthFCF CAGR
124.12%
Industry Style: Growth, Innovation, High Beta
High Growth